

# Angela M Minassian

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1356933/publications.pdf>

Version: 2024-02-01

19  
papers

10,570  
citations

471509

17  
h-index

713466

21  
g-index

26  
all docs

26  
docs citations

26  
times ranked

16728  
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2022, 10, 167-179.	10.7	89
2	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial. <i>Journal of Infection</i> , 2022, 84, 795-813.	3.3	43
3	Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 1131-1141.	9.1	99
4	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. <i>Lancet</i> , The, 2021, 397, 99-111.	13.7	3,887
5	Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. <i>Nature Medicine</i> , 2021, 27, 279-288.	30.7	265
6	T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. <i>Nature Medicine</i> , 2021, 27, 270-278.	30.7	473
7	Mapping immune variation and var gene switching in naive hosts infected with <i>Plasmodium falciparum</i> . <i>ELife</i> , 2021, 10, .	6.0	22
8	Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. <i>Lancet</i> , The, 2021, 397, 881-891.	13.7	979
9	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. <i>Lancet</i> , The, 2021, 397, 1351-1362.	13.7	540
10	Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination. <i>Med</i> , 2021, 2, 701-719.e19.	4.4	73
11	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. <i>Lancet HIV</i> , the, 2021, 8, e474-e485.	4.7	190
12	AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific T <sub>H</sub> 1 response with a diverse TCR repertoire. <i>Science Translational Medicine</i> , 2021, 13, eabj7211.	12.4	80
13	Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. <i>Nature Medicine</i> , 2021, 27, 2032-2040.	30.7	900
14	Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). <i>Lancet</i> , The, 2021, 398, 981-990.	13.7	214
15	Controlled human malaria infection with a clone of <i>Plasmodium vivax</i> with high-quality genome assembly. <i>JCI Insight</i> , 2021, 6, .	5.0	22
16	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCoV-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. <i>Lancet</i> , The, 2021, 398, 2258-2276.	13.7	519
17	Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. <i>Lancet</i> , The, 2020, 396, 467-478.	13.7	2,080
18	Structural basis for inhibition of <i>Plasmodium vivax</i> invasion by a broadly neutralizing vaccine-induced human antibody. <i>Nature Microbiology</i> , 2019, 4, 1497-1507.	13.3	48

#	ARTICLE	IF	CITATIONS
19	Tools for Assessing the Protective Efficacy of TB Vaccines in Humans: in vitro Mycobacterial Growth Inhibition Predicts Outcome of in vivo Mycobacterial Infection. <i>Frontiers in Immunology</i> , 2019, 10, 2983.	4.8	24